Nasdaq:US$25.03 (-0.47) | HKEX:HK$40.85 (-2.05) | AIM:£3.88 (-0.08)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
12
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
4,600
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Corporate Presentation for Investors 2021-12-31
2022 Half-Year Financial Results (Tentative) 2022-08-01 - 2022-08-31
2021 Full Year Financial Results (Tentative) 2022-03-01 - 2022-03-31